AstraZeneca and Merck announced that the Phase III GY004 trial of cediranib in combination with Lynparza compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer failed to meet the primary endpoint.
Could an arthritis medication show promise as a treatment for the symptoms related to the coronavirus? That’s what Regeneron and Sanofi intend to find out.
France-based MedDay Pharmaceuticals announced the company’s MED1003 failed to meet the primary and secondary endpoints in the second pivotal Phase III trial for progressive multiple sclerosis (MS).
Seemingly in response to global uncertainty over the coronavirus outbreak, the stock markets have plunged, numerous conferences are being canceled and biopharma companies are taking action.
Cambridge, Massachusetts-based Acceleron Pharma announced that the company’s Phase II clinical trial of ACE-083 in patients with Charcot-Marie-Tooth disease (CMT) failed to show functional improvement.
Bristol-Myers Squibb’s combination treatment for multiple myeloma failed to hit the endpoint of progression-free survival in a Phase III test.
Over the next six years, 10 drugs that are in the pre-registration phase and expected to launch during 2020 are projected to reach blockbuster status.
Amazon’s Project Gesundheit, a multi-year project including more than 100 people, is focused on finding a cure for the common cold.
GlaxoSmithKline’s unit ViiV Healthcare said the company’s two-drug regimen to treat HIV was as effective in patients given the treatment every two months, as when administered once a month.
AstraZeneca’s treatment options for Stage IV (metastatic) bladder cancer failed to hit the mark of improving overall survival in a Phase III trial.
